Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III ma...

Full description

Saved in:
Bibliographic Details
Main Authors: David A. Reardon, James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, Scott Turner, Sith Sathornsumetee, Jeremy N. Rich, Susan Boulton, Eric S. Lipp, Henry S. Friedman, James J. Vredenburgh
Other Authors: Dana-Farber Cancer Institute
Format: Article
Published: 2018
Subjects:
Biochemistry, Genetics and Molecular Biology
Medicine
Neuroscience
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/13791
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/13791

Similar Items